United States Pediatric Vaccine Market 2017 – Demand, Insights, Analysis, Opportunities Segmentation and Forecast to 2024
Date: Nov-2017 | Id: MACRC-0063 | Geographical Scope: United States | Publisher: DPI Research
United States Pediatric Vaccine market is likely to reach nearly US$ 10 Billion by 2024. Growth in US pediatric vaccine market can be attributed to factors such as increased disease awareness, growing public acceptance, increasing government focus on immunization programs and increased government funding for the vaccine development. The research report titled “United States Pediatric Vaccine Market 2017 – Demand, Insights, Analysis, Opportunities Segmentation and Forecast to 2024” examines the market dynamics, competitive landscape and discusses major trends. The study describes an in–depth analysis of the United States pediatric vaccine market. The report contains a granular analysis of the market segmentation, reveal facts on the market size, volume and revenues and provides forecasts through 2024. The report also provides a deep and thorough evaluation of the top 10 pediatric vaccines by disease indication. On the basis of disease indication, the top 10 pediatric vaccines provide an in-depth analysis of doses administered, number of children being vaccinated and market size. The report also explores detailed description of growth drivers and inhibitors of the United States pediatric vaccine market. The report concludes with the profiles of major players in the United States pediatric vaccine market. The key market players are evaluated on various parameters such as company overview, pediatric vaccine portfolios and latest development & trends of the pediatric vaccine market. Major Pediatric Vaccines (Disease Indication) Covered Under This Report Are: Diphtheria, Tetanus & Pertussis (DTap) Hepatitis A Varicella/Chicken Pox Pneumococcal Haemophilus Influenzae Type B (HIB) Polio Rotavirus Hepatitis B Influenza Pediatric Measles, Mumps & Rubella (MMR) Key Companies Covered in the Report are as follows: Sanofi Pasteur GlaxoSmithKline(GSK) Merck & Co. Pfizer Inc Grifols Key Deliverables in the Study Market Definition for the specified topic along with identification of key drivers and inhibitors for the market It provides a growth map over time to understand the industry growth rate It provides a seven-year forecast assessed based on how the market is predicted to grow It helps in understanding the key product segments and their future It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments A comprehensive list of key market players along with the analysis of their current pediatric vaccines portfolios and latest development and trends.
1. Executive Summary 2. Market Size & Analysis: United States Pediatric Vaccine (2010 – 2024) 3. United States Pediatric Vaccine Market Share and Y–o–Y Growth (%) 4. Key Market Drivers and Inhibitors of the United States Pediatric Vaccine Market 4.1 Market Drivers 4.2 Market Inhibitors 5. United States Pediatric Vaccine Market – By Disease Indication (2010 – 2024) 5.1 Diphtheria, Tetanus & Pertussis (DTap) 5.1.1 Doses Administered (Volume) 5.1.2 Number of Children Being Vaccinated (Volume) 5.1.3 Market Size and Forecast (Value) 5.2 Hepatitis A 5.2.1 Doses Administered (Volume) 5.2.2 Number of Children Being Vaccinated (Volume) 5.2.3 Market Size and Forecast (Value) 5.3 Varicella / Chicken Pox 5.3.1 Doses Administered (Volume) 5.3.2 Number of Children Being Vaccinated (Volume) 5.3.3 Market Size and Forecast (Value) 5.4 Pneumococcal 5.4.1 Doses Administered (Volume) 5.4.2 Number of Children Being Vaccinated (Volume) 5.4.3 Market Size and Forecast (Value) 5.5 Haemophilus Influenzae Type B (HIB) 5.5.1 Doses Administered (Volume) 5.5.2 Number of Children Being Vaccinated (Volume) 5.5.3 Market Size and Forecast (Value) 5.6 Polio 5.6.1 Doses Administered (Volume) 5.6.2 Number of Children Being Vaccinated (Volume) 5.6.3 Market Size and Forecast (Value) 5.7 Rotavirus 5.7.1 Doses Administered (Volume) 5.7.2 Number of Children Being Vaccinated (Volume) 5.7.3 Market Size and Forecast (Value) 5.8 Hepatitis B 5.8.1 Doses Administered (Volume) 5.8.2 Number of Children Being Vaccinated (Volume) 5.8.3 Market Size and Forecast (Value) 5.9 Influenza Pediatric 5.9.1 Doses Administered (Volume) 5.9.2 Number of Children Being Vaccinated (Volume) 5.9.3 Market Size and Forecast (Value) 5.10 Measles, Mumps & Rubella (MMR) 5.10.1 Doses Administered (Volume) 5.10.2 Number of Children Being Vaccinated (Volume) 5.10.3 Market Size and Forecast (Value) 6. Key Companies Analysis 6.1 Sanofi Pasteur 6.1.1 Business Overview 6.1.2 Pediatric Vaccine Portfolios 6.1.3 Pedaitric Vaccine – Latest Development & Trends 6.2 GlaxoSmithKline (GSK) 6.2.1 Business Overview 6.2.2 Pediatric Vaccine Portfolios 6.2.3 Pediatric Vaccine – Latest Development & Trends 6.3 Merck & Co. 6.3.1 Business Overview 6.3.2 Pediatric Vaccine Portfolios 6.3.3 Pediatric Vaccine – Latest Development & Trends 6.4 Pfizer Inc. 6.4.1 Business Overview 6.4.2 Pediatric Vaccine Portfolios 6.4.3 Pediatric Vaccine – Latest Development & Trends 6.5 Grifols 6.5.1 Business Overview 6.5.2 Pediatric Vaccine Portfolios 6.5.3 Pediatric Vaccine – Latest Development & Trends List of Tables: Table 3–1: United States Pediatric Vaccines Market Share (Percent), 2010 – 2016 Table 3–2: United States Pediatric Vaccine Market Share Forecast (Percent), 2017 – 2024 List of Figures: Figure 2–1: United States Pediatric Vaccine Market (Million US$), 2010 – 2016 Figure 2–2: United States Pediatric Vaccines Market Forecast (Million US$), 2017 – 2024 Figure 4–19: DTap Vaccine Doses Administered (in Million), 2010 – 2016 Figure 4–20: DTap Vaccine Doses Administered Forecast (in Million), 2017 – 2024 Figure 4–21: Number of Children Being Vaccinated with DTap Vaccine (in Million),2010 – 2016 Figure 4–22: Number of Children Being Vaccinated with DTap Vaccine Forecast (in Million),2017 – 2024 Figure 4–23: DTap Vaccine Market Value (in Million US$), 2010 – 2016 Figure 4–24: DTap Vaccine Market Value Forecast (in Million US$), 2017 – 2024 Figure 4–43: Hepatitis A Vaccine Doses Administered (in Million), 2010 – 2016 Figure 4–44: Hepatitis A Vaccine Doses Administered Forecast (in Million), 2017 – 2024 Figure 4–45: Number of Children Being Vaccinated with Hepatitis A Vaccine (in Million),2010 – 2016 Figure 4–46: Number of Children Being Vaccinated with Hepatitis A Vaccine Forecast (in Million),2017 – 2024 Figure 4–47: Hepatitis A Vaccine Market Value (in Million US$), 2010 – 2016 Figure 4–48: Hepatitis A Vaccine Market Value Forecast (in Million US$), 2017 – 2024 Figure 4–49: Varicella Vaccine Doses Administered (in Million), 2010–2016 Figure 4–50: Varicella Vaccine Doses Administered Forecast (in Million), 2017 – 2024 Figure 4–51: Number of Children Being Vaccinated with Varicella Vaccine (in Million),2010 – 2016 Figure 4–52: Number of Children Being Vaccinated with Varicella Vaccine Forecast (in Million),2017 – 2024 Figure 4–53: Varicella Vaccine Market Value (in Million US$), 2010 – 2016 Figure 4–54: Varicella Vaccine Market Value Forecast (in Million US$), 2017 – 2024 Figure 4–25: Pneumococcal Vaccine Doses Administered (in Million), 2010 – 2016 Figure 4–26: Pneumococcal Vaccine Doses Administered Forecast (in Million), 2017 – 2024 Figure 4–27: Number of Children Being Vaccinated with Pneumococcal Vaccine (in Million),2010 – 2016 Figure 4–28: Number of Children Being Vaccinated with Pneumococcal Vaccine Forecast (in Million),2017 – 2024 Figure 4–29: Pneumococcal Vaccine Market Value (in Million US$), 2010 – 2016 Figure 4–30: Pneumococcal Vaccine Market Value Forecast (in Million US$), 2017 – 2024 Figure 4–7: HIB Vaccine Doses Administered (in Million), 2010 – 2016 Figure 4–8: HIB Vaccine Doses Administered Forecast (in Million), 2017 – 2024 Figure 4–9: Number of Children Being Vaccinated with HIB Vaccine (in Million),2010 – 2016 Figure 4–10: Number of Children Being Vaccinated with HIB Vaccine Forecast (in Million),2017 – 2024 Figure 4–11: HIB Vaccine Market Value (in Million US$), 2010 – 2016 Figure 4–12: HIB Vaccine Market Value Forecast (in Million US$), 2017 – 2024 Figure 4–13: Polio Vaccine Doses Administered (in Million), 2010 – 2016 Figure 4–14: Polio Vaccine Doses Administered Forecast (in Million), 2017 – 2024 Figure 4–15: Number of Children Being Vaccinated with Polio Vaccine (in Million),2010 – 2016 Figure 4–16: Number of Children Being Vaccinated with Polio Vaccine Forecast (in Million),2017 – 2024 Figure 4–17: Polio Vaccine Market Value (in Million US$), 2010 – 2016 Figure 4–18: Polio Vaccine Market Value Forecast (in Million US$), 2017 – 2024 Figure 4–31: Rotavirus Vaccine Doses Administered (in Million), 2010 – 2016 Figure 4–32: Rotavirus Vaccine Doses Administered Forecast (in Million), 2017 – 2024 Figure 4–33: Number of Children Being Vaccinated with Rotavirus Vaccine (in Million),2010 – 2016 Figure 4–34: Number of Children Being Vaccinated with Rotavirus Vaccine Forecast (in Million),2017 – 2024 Figure 4–35: Rotavirus Vaccine Market Value (in Million US$), 2010 – 2016 Figure 4–36: Rotavirus Vaccine Market Value Forecast (in Million US$), 2017 – 2024 Figure 4–37: Hepatitis B Vaccine Doses Administered (in Million), 2010 – 2016 Figure 4–38: Hepatitis B Vaccine Doses Administered Forecast (in Million), 2017 – 2024 Figure 4–39: Number of Children Being Vaccinated with Hepatitis B Vaccine (in Million),2010 – 2016 Figure 4–40: Number of Children Being Vaccinated with Hepatitis B Vaccine Forecast (in Million),2017 – 2024 Figure 4–41: Hepatitis B Vaccine Market Value (in Million US$), 2010 – 2016 Figure 4–42: Hepatitis B Vaccine Market Value Forecast (in Million US$), 2017 – 2024 Figure 4–55: Influenza Pediatric Vaccine Doses Administered (in Million), 2010 – 2016 Figure 4–56: Influenza Pediatric Vaccine Doses Administered Forecast (in Million), 2017 – 2024 Figure 4–57: Number of Children Being Vaccinated with Influenza Pediatric Vaccine (in Million),2010 – 2016 Figure 4–58: Number of Children Being Vaccinated with Influenza Pediatric Vaccine Forecast (in Million),2017 – 2024 Figure 4–59: Influenza Pediatric Vaccine Market Value (in Million US$), 2010 – 2016 Figure 4–60: Influenza Pediatric Vaccine Market Value Forecast (in Million US$), 2017 – 2024 Figure 4–1: MMR Vaccine Doses Administered (in Million), 2010 – 2016 Figure 4–2: MMR Vaccine Doses Administered Forecast (in Million), 2017 – 2024 Figure 4–3: Number of Children Being Vaccinated with MMR Vaccine (in Million),2010 – 2016 Figure 4–4: Number of Children Being Vaccinated with MMR Vaccine Forecast (in Million),2017 – 2024 Figure 4–5: MMR Vaccine Market Value (in Million US$), 2010 – 2016 Figure 4–6: MMR Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Related reports
United States Influenza Vaccine Market
$1000-$1400
United States Blood Glucose Test Strips Market
$1290-$1990